NEW YORK - Actinium Pharmaceuticals (NYSE:ATNM), Inc. (NYSE AMERICAN: ATNM) has announced positive results from its Phase 3 SIERRA trial, revealing that Iomab-B significantly improved survival outcomes for patients with TP53 mutation-positive relapsed or refractory acute myeloid leukemia (AML). The trial data, presented at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR in San Antonio, Texas, showed a median overall survival of 5.49 months for patients treated with Iomab-B, compared to 1.66 months for those who received conventional care.
The SIERRA trial focused on the efficacy of Iomab-B, a targeted radiotherapy, in overcoming the adverse effects of TP53 mutations, which are typically associated with poor prognosis and limited treatment options in AML patients. According to the trial results, over 50% of TP53 mutation-positive patients achieved complete remission after treatment with Iomab-B, a stark contrast to the 0% remission rate observed in the control group receiving the best available treatment based on physician's choice.
Dr. Avinash Desai, Actinium's Chief Medical Officer, emphasized the desperate need for effective treatments for patients with TP53 mutations and expressed optimism about Iomab-B's potential to improve outcomes for this patient group. The trial also highlighted the robust engraftment achieved with Iomab-B treatment prior to allogeneic hematopoietic cell transplant.
Actinium Pharmaceuticals is advancing its pipeline candidates, including Iomab-B and Actimab-A, with the goal of improving survival outcomes for patients with relapsed and refractory AML. The company is also planning to expand the use of Iomab-B for other blood cancers and further develop Iomab-ACT to enhance cell and gene therapy outcomes.
The information presented in this article is based on a press release statement from Actinium Pharmaceuticals, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.